Full Title
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (ANHL1931) (CIRB)Purpose
Treatment for primary mediastinal B-cell lymphoma (PMBCL) includes chemotherapy plus an immunotherapy drug called rituximab. Rituximab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells.
Nivolumab is a type of immunotherapy drug that boosts the immune system to find and kill cancer cells. In this study, researchers want to see if giving nivolumab with chemo-immunotherapy is better than chemo-immunotherapy alone. The people in this study have PMBCL that has not yet been treated.
If you join this study, you will be randomly assigned to get chemo-immunotherapy with or without nivolumab. Nivolumab and chemo-immunotherapy are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have newly diagnosed PMBCL.
- Have normal heart and kidney function.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 2 or older.
Contact
For more information about this study and to see if you or your child can join, please contact 1-833-MSK-KIDS.